In our latest Q&A series, Amy Carroll, our new SVP of Medical Affairs, shares what drew her to join George Medicines, explains her guiding philosophy in medical affairs, and outlines what lies ahead for the company.
- Congratulations on your new role as SVP of Medical Affairs at George Medicines! What drew you to this position, and what excites you most about joining the company?
I am delighted to have joined the George Medicines team.
What immediately drew me to the organization was the strategic focus of the company and its highly pragmatic approach to address the most common risk factor for death in the world today, hypertension. Hypertension is the nexus of pathophysiology and cardiorenal metabolic disease progression, on which I have worked my entire scientific career. Now, I have the opportunity to help bring to market the innovation of a single pill combination therapy that has the potential to improve the lives of patients and those who care for them.
What excites me most is the opportunity to bring my experiences across medical affairs, clinical development and commercialization to help shape the medical strategy at such a pivotal time for the organization and to bring forward new medicines truly needed throughout the world.
- You have extensive experience across the industry in medical affairs. How has your expertise prepared you for this role, and what unique perspectives do you bring to George Medicines?
The leadership team here, including the experienced Board of Directors and contributions of The George Institute for Global Health, is such a unique paradigm. I am privileged to be a part of such an accomplished team.
My background in research and development and medical affairs has been strongly focused on cardiometabolic diseases, the clinical sequelae and bringing new therapies to market. I’ve led Medical Affairs teams through product launches, regulatory engagements and real-world evidence generation, all of which are critical for a growing company like George Medicines.
What I bring to this role is a strategic understanding of how to integrate clinical development with the near-term focus of patient needs and commercialization of a medicine, while balancing the long-term trajectory of new drug pipeline development in ever-evolving healthcare sectors.
- What is your guiding philosophy when it comes to your role, and how do you see it driving success in a company like George Medicines?
Medical affairs links research science with the needs of the broader clinical healthcare community. We work directly with providers to understand their needs and the practical needs of the patient, and to translate scientific findings in ways that are going to help individuals make the most informed medical decision possible. It is our goal to continue to advance medicine in ways that are scientifically sound and clinically meaningful through additional studies positioned for real-world outcomes.
My philosophy has always been to ensure that medical strategies are built on scientific integrity while staying closely aligned with patient and market needs. At George Medicines, this approach means ensuring that our therapies are backed by strong clinical evidence, engaging with healthcare professionals to foster dialogue to better understand unmet needs, and working closely with regulatory and payer stakeholders to support broad access. Ultimately, the success of any medical innovation depends not just on its efficacy, but also on its ability to reach and benefit the patients who need it most.
- George Medicines is focused on delivering innovative treatments for cardiometabolic diseases. How do you see the company making a meaningful impact in this space?
Despite advances in healthcare, cardiometabolic diseases have remained the leading cause of death globally for decades. A vast majority of patients struggle with access, adherence and treatment complexity. George Medicines is tackling this challenge with a practical yet innovative approach —developing unique optimized fixed-dose combinations to enhance efficacy while simplifying treatment regimens that confound safety and access concerns.
The approach we are taking has the potential to shift treatment paradigms, particularly in underserved populations where treatment adherence and accessibility remain major barriers. Underserved populations exist in nations of all socioeconomic levels and, beyond the science, George Medicines is also committed to global health equity. That broader vision is what makes this company’s work so impactful.
- Looking at the here and now, what are your current priorities? And what’s on your long-term radar for the Medical Affairs function at George Medicines
Right now, my focus is on strengthening the medical affairs function to support the company’s near-term milestones. This includes ensuring a successful new drug application in the United States and expanding that to other regions of the world, expanding scientific engagement with key opinion leaders, shaping our evidence generation strategy and ensuring that our communications effectively convey the clinical value proposition of our therapies.
In the long term, my goal is to position medical affairs as a strategic driver of George Medicines’ growth. This means fostering strong partnerships with healthcare providers, regulatory bodies, and patient advocacy groups to support broad adoption of our treatments. Generation of real-world evidence will also be a major focus, so we are continuously generating data on the impact of our therapies to inform future innovation and policy decisions.
At the end of the day, success for George Medicines means delivering treatments that truly make a difference in patients’ lives. My role is to help ensure that happens in an integrated approach.